Document is current
Any future updates will be listed below
-
Authors
Sjödin, Simon http://orcid.org/0000-0003-3125-0371
Brinkmalm, Gunnar
Öhrfelt, Annika
Parnetti, Lucilla
Paciotti, Silvia
Hansson, Oskar
Hardy, John
Blennow, Kaj
Zetterberg, Henrik
Brinkmalm, Ann
-
Funding
Funding for this research was provided by:
Eivind and Elsa K:Son Sylvans Foundation (-)
Märtha and Gustaf Ågrens Foundation (-)
Hjärnfonden (-, -)
Torsten Söderbergs Stiftelse (-)
Alzheimerfonden (-, -)
Stiftelsen för Gamla Tjänarinnor (-, -, -, -)
Vetenskapsrådet (20112-2288, -, 2013-2546)
Parkinsonfonden (-)
Demensförbundet (-)
Åhlén-stiftelsen (-)
Gun och Bertil Stohnes Stiftelse (-, -)
Stiftelserna Wilhelm och Martina Lundgrens (-)
European Research Council (-, 681712)
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (-)
Knut och Alice Wallenbergs Stiftelse (2013.0180)
- License Information
-
More Information
Article History
Received: 20 June 2019
Accepted: 22 August 2019
First Online: 14 September 2019
Ethics approval and consent to participate
: All the procedures of the present article were performed following the Helsinki Declaration, after approval by local ethical committees.
: Not applicable.
: HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. HZ has served at advisory boards of Roche Diagnostics and Eli Lilly. KB has served as a consultant or at advisory boards for Alzheon, Eli Lilly, Fujirebio Europe, IBL International, and Roche Diagnostics. OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, OH has received consultancy/speaker fees (paid to the institution) from Lilly, Roche, and Fujirebio. LP has received research reagents from Fujirebio and Euroimmun. LP has also served as Member of Advisory Boards for Fujirebio, IBL, Roche, and Merck. The other authors declare that they have no competing interests.
